Hematologic Oncology | Oncology Today with Dr Neil Love: Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma

Research To Practice | Oncology Videos

Featuring an interview with Dr Gilles Salles on the following topics:

• Novel and emerging strategies for diffuse large B-cell lymphoma (DLBCL) (0:00)
• Available efficacy and safety data with the antibody-drug conjugate polatuzumab vedotin for DLBCL (1:01)
• Mechanism of action of selinexor, the novel selective inhibitor of nuclear export; key efficacy and safety findings from the pivotal Phase II SADAL trial of selinexor for relapsed/refractory (R/R) DLBCL (8:15)
• Emerging data with tafasitamab and biologic rationale for combining it with lenalidomide for DLBCL; benefits and risks of tafasitamab/lenalidomide for patients with R/R DLBCL (14:58)
• Role of chimeric antigen receptor (CAR) T-cell therapies in the management of DLBCL (25:18)
• Therapeutic algorithm for patients with DLBCL (31:35)
• Biologic rationale for the investigation of the novel bispecific antibody mosunetuzumab; activity and tolerability of mosunetuzumab in DLBCL (38:46)
• Efficacy of the antibody-drug conjugate loncastuximab tesirine and the anti-CD47 antibody magrolimab; role of venetoclax-based therapy for DLBCL (45:34)
• Case: A man in his late 60s with DLBCL receives polatuzumab vedotin in combination with bendamustine/rituximab (B/R) after disease progression on 3 lines of therapy, including autologous stem cell transplant and CAR T-cell therapy (53:30)
• Sequencing of tafasitamab/lenalidomide, polatuzumab vedotin/BR and selinexor for patients with R/R DLBCL (1:01:32)
• Response to bispecific antibodies in patients with DLBCL (1:04:59)
• Case: A woman in her mid-70s receives tafasitamab and lenalidomide after experiencing disease relapse on R-CHOP for Stage IV DLBCL (1:09:22)
• Case: A man in his early 70s presents with DLBCL with C-MYC and Bcl-2 translocation (1:11:21)

CME information and select publications